Literature DB >> 2620294

Cytotoxic and DNA-damaging effects of 1,2-bis(sulfonyl)hydrazines on human cells of the Mer+ and Mer- phenotype.

G Pratviel1, K Shyam, A C Sartorelli.   

Abstract

A series of 1,2-bis(sulfonyl)hydrazines with the capacity to function as alkylating agents have been evaluated for their toxicity towards Mer- HT29 and Mer- BE cells, and for their ability to produce DNA damage expressed as single-strand breaks and DNA interstrand cross-links. Compounds of this class with methylating potential showed a marked difference in their capacity to inhibit the growth of Mer- and Mer+ cells, being considerably more toxic to BE Mer- cells. Dose-dependent DNA single-strand breaks were induced by these agents, with the quantity of breaks produced in Mer- and Mer+ cells being essentially the same. Maintenance of these lesions did not appear to explain the differential in toxicity to BE and HT29 cells. A chloroethylating compound of this class was also more toxic to Mer- BE cells than to Mer+ HT29 cells, but the differential toxicity was considerably less than that of the methylating agents of the series. The chloroethylating agent did not produce measurable single-strand breaks of the DNA of treated cells, but caused more DNA interstrand cross-links in Mer- cells than in Mer+ cells. Thus, DNA interstrand cross-links may be at least in part responsible for the cell kill produced by this agent. The findings suggest that methylating and chloroethylating derivatives of the 1,2-bis(sulfonyl)hydrazine family have different biochemical determinants of their cytodestructive actions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2620294

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN: 0305-7232


  3 in total

1.  Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat.

Authors:  John Mao; Yang Xu; Diana Wu; Bijan Almassain
Journal:  AAPS PharmSci       Date:  2002

2.  Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.

Authors:  G Krishna; W F Hodnick; W Lang; X Lin; S Karra; J Mao; B Almassian
Journal:  AAPS PharmSciTech       Date:  2001-08-26       Impact factor: 3.246

3.  A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.

Authors:  John Murren; Manuel Modiano; Shivaani Kummar; Caroline Clairmont; Merrill Egorin; Edward Chu; Mario Sznol
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.651

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.